Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
London School of Economics and Political Science
Study ID
NCT07731425
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • FDA explanation for progression-free survival (control) — OTHER
    Progression-free survival
  • FDA explanation for progression-free survival with overall survival data — OTHER
    The description, 'progression-free survival', along with data on overall survival.
  • NCI explanation for progression-free survival — OTHER
    The description, 'the length of time during and after treatment that a patient lived with the cancer but it did not get worse'.
  • NCI explanation for progression-free survival with overall survival data — OTHER
    The description, 'the length of time during and after treatment that a patient lived with the cancer but it did not get worse', along with data on overall survival.
  • Plain-language explanation of progression-free survival — OTHER
    The description, 'the length of time until a test showed the cancer grew, spread, or worsened'.
  • Plain-language explanation of progression-free survival with overall survival data — OTHER
    The description, 'the length of time until a test showed the cancer grew, spread, or worsened', along with data on overall survival.

Study Details

This study of current or former cancer patients will evaluate whether communicating data on overall survival data in addition to information on progression-free improves the accuracy of cancer patients' expectations about the survival benefits of new cancer drugs

Key Dates

First listed
Jul 28, 2026
Start date
Aug 1, 2026
Status verified
Jul 2026
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026

Study Design

Enrollment
3,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Placebo Comparator: FDA explanation for progression-free survival (control)
  • Experimental: FDA explanation for progression-free survival with overall survival data
  • Experimental: NCI explanation for progression-free survival
  • Experimental: NCI explanation for progression-free survival with overall survival data
  • Experimental: Plain-language explanation of progression-free survival
  • Experimental: Plain-language explanation of progression-free survival with overall survival data

Primary Outcome Measure

Accuracy of expectations about the survival benefits of a new cancer drug approved based on progression-free survival [ Time Frame: Assessed immediately after the intervention ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Harvard Medical School and Harvard Pilgrim Health Care InstituteBostonMassachusetts02215
Avi Cherla
[email protected]
020 7852 3727

Find similar trials in Boston, MA

By research site
Harvard Medical School and Harvard Pilgrim Health Care Institute· Boston, MA

Related Studies